Vaccine equity: Past, present, and future

Graaf, Rieke van der; Browne, Joyce L.; Baidjoe, Amrish

doi:10.1016/j.xcrm.2022.100551

Cited by 10 publications

(19 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

Section: Discussionmentioning

confidence: 99%

“…Many of these concentrate on vaccine distribution, but, as van der Graaf et al have pointed out, there is scope for a model of vaccine equity that extends to the full vaccine life cycle, taking production and health systems contexts into account so that equity is seen as more than 'needles in arms'. 68 Overall, the terminology used in the literature and the media is heterogeneous and used inconsistently. Papers rarely articulate the sociopolitical contexts in which their arguments are situated, although these are integral to concepts of equity.…”

Section: Meta-narrative 4: Ethics and Moralitymentioning

confidence: 99%

See 1 more Smart Citation

Vaccine equity in COVID-19: a meta-narrative review

et al. 2022

View full text Add to dashboard Cite

The topic of inequitable vaccine distribution has been widely discussed by academics, journalists and policy-makers in the context of the COVID-19 pandemic. However, research into perceptions of vaccine equity has been particularly neglected, resulting in a lack of universal understanding of vaccine equity. To address this, we conducted a meta-narrative review on COVID-19 vaccine equity according to the Realist And MEta-narrative Evidence Syntheses: Evolving Standards (RAMESES) publication standard. The review included articles published between January 2020 and September 2021. It aims to (1) identify research traditions that have considered this topic and investigate how it has been conceptualised; (2) explore any potential differences in understandings of the concept of vaccine equity adopted by distinct research groups; and (3) investigate the angles from which authors based their recommendations on how vaccine equity can be achieved. Five meta-narratives from the literature across various research traditions are identified, contextualised and discussed: frameworks and mechanisms for vaccine allocation, global health law, vaccine nationalism, ethics and morality, and reparative justice. Our findings indicate the need for a comparative review of existing global COVID-19 allocation frameworks, with a focus on explicating understandings of vaccine equity. COVID-19 will not be the last health crisis the world confronts. Heterogeneity in the academic literature is part of the way concepts are debated and legitimised, but in the interests of global public health policy-making, it is desirable to reach a consensus on what constitutes progress on equitable development, production, distribution and research.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Meta-narrative 4: Ethics and Moralitymentioning

confidence: 99%

Vaccine equity in COVID-19: a meta-narrative review

et al. 2022

View full text Add to dashboard Cite

show abstract

“…The global public health crisis and the social disruption caused by the coronavirus disease 2019 (COVID-19) pandemic have prompted the emergency use of speedily developed vaccines. As of October 2022, over 12 billion doses had been administered globally (WHO, 2022-10-25), although the vaccination distribution is significantly unbalanced (van der Graaf et al, 2022). Previous studies have reported that NAbs responses elicited by an inactivated vaccine (CoronaVac ® ) and an mRNA vaccine (BNT162b2) persisted for 6-8 months after full-schedule vaccination and declined to varying degrees (Falsey et al, 2021; Zeng et al, 2021).…”

Section: Introductionmentioning

confidence: 99%

Longitudinal proteomic investigation of COVID-19 vaccination

Wang

Zhu

Sun

et al. 2022

Preprint

View full text Add to dashboard Cite

Although the development of COVID-19 vaccines has been a remarkable success, the heterogeneous individual antibody generation and decline over time are unknown and still hard to predict. In this study, blood samples were collected from 163 participants who next received two doses of an inactivated COVID-19 vaccine (CoronaVac) at a 28-day interval. Using TMT-based proteomics, we identified 1715 serum and 7342 peripheral blood mononuclear cells (PBMCs) proteins. We proposed two sets of potential biomarkers (seven from serum, five from PBMCs) using machine learning, and predicted the individual seropositivity 57 days after vaccination (AUC = 0.87). Based on the four PBMC's potential biomarkers, we predicted the antibody persistence until 180 days after vaccination (AUC = 0.79). Our data highlighted characteristic hematological host responses, including altered lymphocyte migration regulation, neutrophil degranulation, and humoral immune response. This study proposed potential blood-derived protein biomarkers for predicting heterogeneous antibody generation and decline after COVID-19 vaccination, shedding light on immunization mechanisms and individual booster shot planning.

show abstract

“…In preparing for future pandemics, lessons of vaccine inequity must be used to correct structural imbalances by adopting a normative approach towards health equity. 11 …”

mentioning

confidence: 99%

“…As of 12 April 2022, the average vaccination rate in the EMR was only 42%, with a range of 1%–97%; 4 of 22 countries (18%) still had coverage rates of less than 10% and only 11 (50%) had reached the country-specific target of 40% by the end of 2021. In preparing for future pandemics, lessons of vaccine inequity must be used to correct structural imbalances by adopting a normative approach towards health equity 11…”

mentioning

confidence: 99%